Skip to main content

Table 1 Baseline characteristics of patients involved in the study

From: Comparative analysis of the phosphate-binding effects of sucroferric oxyhydroxide, ferric citrate, and lanthanum carbonate

  n = 309 (FC = 101, SF = 82, LC = 126) Mean ± SD
Age (years) FC 62.9 ± 12.8
SF 63.6 ± 13.3
LC 61.7 ± 11.4
Total 62.6 ± 12.4
BMI (kg/m2) FC 23.1 ± 4.4
SF 22.7 ± 4.6
LC 23.7 ± 3.8
Total 23.2 ± 4.2
HD duration (months) FC 59.5 ± 55.0
SF 70.6 ± 78.9
LC 71.4 ± 54.9
Total 67.3 ± 62.1
Hb g/dL FC 10.7 ± 1.0
SF 11.0 ± 1.2
LC 10.9 ± 0.9
Total 10.9 ± 1.0
Pi mg/dL FC 6.172 ± 1.6339
SF 6.216 ± 1.2109
LC 5.948 ± 1.4938
Total 6.093 ± 1.4726
Gender   F M
FC 27.7% 72.3%
SF 37.8% 62.2%
LC 27.0% 73.0%
DM/non-DM   Non-DM DM
FC 68.3% 31.7%
SF 62.2% 37.8%
LC 57.1% 42.9%
Combined drug FC 65/101 64.4%
SF 57/82 69.5%
LC 54/126 42.9%
Total 176/311 57.0%
  1. Combined drug: includes sevelamer and a Ca-containing drug
  2. DM diabetes mellitus, BMI body mass index, HD hemodialysis